首頁 > 市場調查報告書 > 製藥

藥物開發開發業務受託機關

市場調查報告書

商品編碼

1489248

全球製藥 CDMO 市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

Global Pharmaceutical CDMO Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年05月01日 | 出版商:

Value Market Research | 英文 170 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球醫藥 CDMO 市場需求預計將從 2023 年的 1,794.7 億美元達到近 3,516.4 億美元的市場規模，2024-2032 年研究期間複合年成長率為 7.76%。

製藥CDMO（合約開發和製造組織）為製藥公司提供全面的服務，包括藥物開發、製造和包裝。這些組織從藥物配方的初始階段到大規模生產和分銷為製藥公司提供支援。 CDMO 提供藥物生命週期各個方面的專業知識，包括臨床試驗、法規遵循和品質控制。與 CDMO 合作使製藥公司能夠利用專業知識和基礎設施，加快上市時間並降低成本，同時確保藥品生產的高安全性和有效性標準。

市場動態

製藥 CDMO（合約開發和製造組織）市場的成長是由製藥外包需求不斷成長推動的，因為公司尋求簡化營運、降低成本並專注於研究和行銷等核心能力。藥物開發的複雜性以及對專業技能和設備的需求導致許多製藥公司依賴 CDMO 進行開發和製造流程。此外，生物製劑和生物相似藥生產的成長大大增加了對製藥 CDMO 的需求，因為這些複雜的分子需要專門的製造能力。製造流程的技術進步，例如連續製造和一次性技術，進一步增強了 CDMO 的吸引力。

個人化醫療和利基療法的成長趨勢也有助於市場成長，因為這些需要 CDMO 可以提供的靈活且可擴展的生產解決方案。此外，監管壓力和遵守嚴格品質標準的需求使 CDMO 對於尋求降低風險和確保產品品質的製藥公司來說是一個有吸引力的選擇。新興市場製藥業的不斷擴張和藥物開發投資的增加推動了製藥 CDMO 市場的發展。然而，監管合規挑戰和競爭壓力可能會挑戰未來幾年的市場成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球製藥 CDMO 市場的各個細分市場進行了包容性評估。製藥 CDMO 產業的成長和趨勢為本研究提供了整體方法。

市場區隔

製藥 CDMO 市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按申請

傳染性疾病
腫瘤學
神經系統疾病

按工作流程

商業的
臨床

按產品分類

合成
製造業
藥物
應用程式介面

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的製藥 CDMO 市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。醫藥CDMO市場的主要參與者包括藥明康德、康泰倫特公司、艾伯維合約製造公司、龍沙集團、贏創工業股份公司、Patheon、Siegfried Holding AG、Recipharm AB、Aenova Group、CordenPharma、Jubilant Life Sciences Ltd.、Almac Group ，Piramal Pharma Solutions，Cambrex Corporation，法雷瓦。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：製藥 CDMO 公司的競爭格局

醫藥CDMO市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

頂級公司市佔率分析
市場集中度
WuXi AppTec

公司簡介
公司收入
產品
最近的發展

Catalent Inc.

公司簡介
公司收入
產品
最近的發展

AbbVie Contract Manufacturing

公司簡介
公司收入
產品
最近的發展

Lonza Group AG

公司簡介
公司收入
產品
最近的發展

Evonik Industries AG

公司簡介
公司收入
產品
最近的發展

Patheon

公司簡介
公司收入
產品
最近的發展

Siegfried Holding AG

公司簡介
公司收入
產品
最近的發展

Recipharm AB

公司簡介
公司收入
產品
最近的發展

Aenova Group

公司簡介
公司收入
產品
最近的發展

CordenPharma

公司簡介
公司收入
產品
最近的發展

Jubilant Life Sciences Ltd.

公司簡介
公司收入
產品
最近的發展

Almac Group

公司簡介
公司收入
產品
最近的發展

Piramal Pharma Solutions

公司簡介
公司收入
產品
最近的發展

Cambrex Corporation

公司簡介
公司收入
產品
最近的發展

Fareva

公司簡介
公司收入
產品
最近的發展

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR112114744

The global demand for Pharmaceutical CDMO Market is presumed to reach the market size of nearly USD 351.64 Billion by 2032 from USD 179.47 Billion in 2023 with a CAGR of 7.76% under the study period 2024-2032.

A pharmaceutical CDMO (Contract Development and Manufacturing Organization) provides comprehensive services to pharmaceutical companies, including drug development, manufacturing, and packaging. These organizations support pharmaceutical firms from the initial stages of drug formulation to large-scale production and distribution. CDMOs offer expertise in various aspects of the drug lifecycle, including clinical trials, regulatory compliance, and quality control. Partnering with a CDMO allows pharmaceutical companies to leverage specialized knowledge and infrastructure, accelerating time-to-market and reducing costs while ensuring high safety and efficacy standards in drug production.

MARKET DYNAMICS

The growth of the pharmaceutical CDMO (Contract Development and Manufacturing Organization) market is driven by the increasing demand for pharmaceutical outsourcing, as companies seek to streamline operations, lower costs, and focus on core competencies such as research and marketing. The complexity of drug development and the need for specialized skills and equipment has led many pharmaceutical companies to rely on CDMOs for development and manufacturing processes. Additionally, the rise in biologics and biosimilar production has significantly boosted the demand for Pharmaceutical CDMOs, as these complex molecules require specialized manufacturing capabilities. Technological advancements in manufacturing processes, such as continuous manufacturing and single-use technologies, have further enhanced the appeal of CDMOs.

The growing trend towards personalized medicine and niche therapeutics also contributes to market growth, as these require flexible and scalable production solutions that CDMOs can provide. Moreover, regulatory pressures and the need for compliance with stringent quality standards make CDMOs an attractive option for pharmaceutical companies looking to mitigate risks and ensure product quality. The expanding pharmaceutical industry in emerging markets and increased investment in drug development drive the pharmaceutical CDMO market. However, regulatory compliance challenges and competitive pressures may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Pharmaceutical CDMO. The growth and trends of Pharmaceutical CDMO industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Pharmaceutical CDMO market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

Infectious Diseases
Oncology
Neurological Disorders

By Workflow

Commercial
Clinical

By Product

Synthesis
Manufacturing
Drug
API

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Pharmaceutical CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Pharmaceutical CDMO market include WuXi AppTec, Catalent Inc., AbbVie Contract Manufacturing, Lonza Group AG, Evonik Industries AG, Patheon, Siegfried Holding AG, Recipharm AB, Aenova Group, CordenPharma, Jubilant Life Sciences Ltd., Almac Group, Piramal Pharma Solutions, Cambrex Corporation, Fareva. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. PHARMACEUTICAL CDMO - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Application
- 3.7.2 Market Attractiveness Analysis By Workflow
- 3.7.3 Market Attractiveness Analysis By Product
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL PHARMACEUTICAL CDMO MARKET ANALYSIS BY APPLICATION

5.1. Overview By Application
5.2. Historical and Forecast Data Analysis By Application
5.3. Infectious Diseases Historic and Forecast Sales By Regions
5.4. Oncology Historic and Forecast Sales By Regions
5.5. Neurological Disorders Historic and Forecast Sales By Regions

6. GLOBAL PHARMACEUTICAL CDMO MARKET ANALYSIS BY WORKFLOW

6.1. Overview By Workflow
6.2. Historical and Forecast Data Analysis By Workflow
6.3. Commercial Historic and Forecast Sales By Regions
6.4. Clinical Historic and Forecast Sales By Regions

7. GLOBAL PHARMACEUTICAL CDMO MARKET ANALYSIS BY PRODUCT

7.1. Overview By Product
7.2. Historical and Forecast Data Analysis By Product
7.3. Synthesis Historic and Forecast Sales By Regions
7.4. Manufacturing Historic and Forecast Sales By Regions
7.5. Drug Historic and Forecast Sales By Regions
7.6. API Historic and Forecast Sales By Regions

8. GLOBAL PHARMACEUTICAL CDMO MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE PHARMACEUTICAL CDMO COMPANIES

9.1. Pharmaceutical CDMO Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF PHARMACEUTICAL CDMO INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. WuXi AppTec
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Catalent Inc.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. AbbVie Contract Manufacturing
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Lonza Group AG
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Evonik Industries AG
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Patheon
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Siegfried Holding AG
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Recipharm AB
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Aenova Group
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. CordenPharma
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Jubilant Life Sciences Ltd.
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. Almac Group
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments
10.15. Piramal Pharma Solutions
- 10.15.1 Company Overview
- 10.15.2 Company Revenue
- 10.15.3 Products
- 10.15.4 Recent Developments
10.16. Cambrex Corporation
- 10.16.1 Company Overview
- 10.16.2 Company Revenue
- 10.16.3 Products
- 10.16.4 Recent Developments
10.17. Fareva
- 10.17.1 Company Overview
- 10.17.2 Company Revenue
- 10.17.3 Products
- 10.17.4 Recent Developments